Cost-minimization analysis of dimethyl fumarate in the treatment of relapsing multiple sclerosis
- VernacularTitle:富马酸二甲酯治疗复发型多发性硬化的最小成本分析
- Author:
Wei LI
1
;
Yizhu SUN
1
;
Jia FANG
2
;
Jian YIN
3
Author Information
1. School of International Pharmaceutical Business，China Pharmaceutical University，Nanjing 211198，China
2. Tianjin Happy Life Technology Co.，Ltd.，Shanghai 200030，China
3. Institute of Geriatric Medicine，Chinese Academy of Medical Sciences，Beijing 100730，China
- Publication Type:Journal Article
- Keywords:
dimethyl fumarate;
fingolimod;
relapsing
- From:
China Pharmacy
2022;33(24):3005-3009
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the cost-effectiveness of dimethyl fumarate versus fingolimod in the treatment of relapsing multiple sclerosis （RMS）. METHODS The cost-effectiveness of dimethyl fumarate versus fingolimod in the treatment of RMS was evaluated with cost-minimization analysis from the perspective of China’s health system. The research period of the model was 2 years， and the discount rate was 5%. Costs included drug costs， treatment monitoring costs and adverse reaction disposal costs. Relevant parameters were from published literature， government documents and expert interviews. A one-way sensitivity analysis of the results and a scenario analysis of the model duration were performed. RESULTS In existing clinical studies， indirect meta-analysis results of different dimensions showed that dimethyl fumarate and fingolimod were similar in clinical efficacy. Within 2 years of the model simulation， total cost per patient using dimethyl fumarate was 91 756.3 yuan and that of using fingolimod was 163 761.5 yuan. The use of dimethyl fumarate was associated with savings of 72 005.2 yuan compared with fingolimod. When extending study horizon to 3 years， the cost savings with the use of dimethyl fumarate increased to 105 420.8 yuan， compared with fingolimod. The most influential factor on the results of the basic analysis was the drug treatment cost of fingolimod. Within the parameter fluctuation range of sensitivity analysis， the incremental costs were all negative， and the basic analysis results were robust. CONCLUSIONS Based on a health system perspective， dimethyl fumarate is more cost-effective than fingolimod in the treatment of RMS.
